GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (XTAE:PLUR) » Definitions » Debt-to-Revenue

Pluri (XTAE:PLUR) Debt-to-Revenue : 39.59 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Pluri Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pluri's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₪2.15 Mil. Pluri's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₪103.63 Mil. Pluri's annualized Revenue for the quarter that ended in Dec. 2024 was ₪2.67 Mil. Pluri's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 39.59.


Pluri Debt-to-Revenue Historical Data

The historical data trend for Pluri's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri Debt-to-Revenue Chart

Pluri Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.95 N/A 123.08 104.23 90.84

Pluri Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.54 106.08 77.03 23.68 39.59

Competitive Comparison of Pluri's Debt-to-Revenue

For the Biotechnology subindustry, Pluri's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pluri's Debt-to-Revenue falls into.


;
;

Pluri Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pluri's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.018 + 104.905) / 1.177
=90.84

Pluri's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.148 + 103.634) / 2.672
=39.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Pluri Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pluri's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pluri Business Description

Traded in Other Exchanges
Address
MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.